Sequel Medical Inc

Sequel Med Tech develops automated insulin delivery (AID) systems for people with diabetes, primarily Type 1 diabetes. The company's flagship product is the twiist Automated Insulin Delivery System, powered by the Tidepool Loop algorithm, which automatically adjusts basal insulin delivery based on continuous glucose monitoring. Sequel addresses accessibility barriers in AID adoption by delivering affordable insulin therapy through pharmacy channels rather than traditional medical device distribution. The company serves multiple markets: healthcare providers and people with diabetes (via twiist consumer platform), employers and health plan consultants (via Sequel Connect), and pharmaceutical companies developing innovative drug delivery solutions. The twiist system features precise measurement technology for accurate insulin delivery and is designed for everyday wearability. Sequel's approach emphasizes simplified access to revolutionary diabetes management technology, with real-world evidence supporting clinically meaningful benefits. The company continues to advance diabetes care technology and explore next-generation drug delivery partnerships.